| abstract |
The present invention provides a pharmaceutical for the prevention or treatment of cervical cancer or head and neck cancer comprising rosmarinic acid methyl ester (RAME), an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. As a composition, more specifically, it inhibits the mammalian target of rapamycin (mTOR) / Ribosomal S6 kinase 1 (S6K1) signaling pathway, induces autophagy or apoptosis, and resists cisplatin. It has been found that reduction can provide a therapeutic strategy to induce improvement of cervical or head and neck cancer and to overcome cisplatin resistance of cervical or head and neck cancer cells, in particular by utilizing the S6K1 signaling inhibitory effect, It may be widely used in the development of cervical cancer therapy using the mechanism of action. |